Payment overview · 2025
General Payments
$769.82
41 reported records · 14 companies
Healthcare provider profile · identity verified
Fareha Rahim, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WATKINSVILLE, GA · NPI 1144241126
Verified facts
What the public records show
CMS Open Payments records show Fareha Rahim, MD received $769.82 in general payments during 2025 across 41 reported records.
Novo Nordisk Inc accounted for 29.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Jardiance by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $228.09 | 29.6% | 16 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $98.41 | 12.8% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $91.81 | 11.9% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $86.38 | 11.2% | 4 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $49.15 | 6.4% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.39 | 5.4% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $35.00 | 4.5% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $30.16 | 3.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.54 | 2.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.55 | 2.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.37 | 2.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.19 | 2.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.20 | 2.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.58 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $769.82 | 41 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $145.34 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $82.75 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $70.80 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $56.72 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $56.72 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $56.72 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $53.46 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $52.03 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $49.15 | 3 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $46.66 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $45.15 | 2 | 2025 |
Source payment records
|
|||||
| SIMPONI ARIA Normalized: simponi aria |
Biological | Janssen Biotech, Inc. | $35.00 | 1 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $35.00 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $33.53 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $30.16 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $29.66 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $21.54 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.55 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.37 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 132 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 132 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 94 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
132 | 34 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
132 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
132 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
94 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
49 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 655 | 201 |
| Levothyroxine Sodium | Levothyroxine Sodium | 622 | 160 |
| Atorvastatin Calcium | Atorvastatin Calcium | 610 | 186 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 380 | 131 |
| Lisinopril | Lisinopril | 351 | 111 |
| Metformin Hcl | Metformin Hcl | 347 | 104 |
| Hydrochlorothiazide | Hydrochlorothiazide | 314 | 101 |
| Gabapentin | Gabapentin | 276 | 70 |
| Losartan Potassium | Losartan Potassium | 261 | 84 |
| Simvastatin | Simvastatin | 247 | 68 |
| Meloxicam | Meloxicam | 219 | 77 |
| Trazodone Hcl | Trazodone Hcl | 206 | 67 |
| Alendronate Sodium | Alendronate Sodium | 185 | 58 |
| Escitalopram Oxalate | Escitalopram Oxalate | 183 | 60 |
| Montelukast Sodium | Montelukast Sodium | 181 | 56 |
| Omeprazole | Omeprazole | 178 | 64 |
| Sertraline Hcl | Sertraline Hcl | 165 | 58 |
| Metoprolol Tartrate | Metoprolol Tartrate | 164 | 40 |
| Famotidine | Famotidine | 147 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 141 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 139 | 40 |
| Ezetimibe | Ezetimibe | 136 | 49 |
| Jardiance | Empagliflozin | 132 | 34 |
| Mounjaro | Tirzepatide | 132 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 127 | 53 |
| Zolpidem Tartrate | Zolpidem Tartrate | 124 | 44 |
| Azelastine Hcl | Azelastine Hcl | 123 | 49 |
| Synthroid | Levothyroxine Sodium | 115 | 29 |
| Tramadol Hcl | Tramadol Hcl | 115 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 114 | 32 |
| Alprazolam | Alprazolam | 107 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 101 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 96 | 28 |
| Ozempic | Semaglutide | 94 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 93 | 23 |
| Metformin Hcl Er | Metformin Hcl | 93 | 35 |
| Valsartan | Valsartan | 93 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 92 | 32 |
| Fenofibrate | Fenofibrate Nanocrystallized | 85 | 21 |
| Furosemide | Furosemide | 83 | 28 |
| Potassium Chloride | Potassium Chloride | 83 | 24 |
| Clonazepam | Clonazepam | 82 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 81 | 33 |
| Bupropion Hcl | Bupropion Hcl | 80 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 80 | 36 |
| Bupropion Xl | Bupropion Hcl | 78 | 22 |
| Methylprednisolone | Methylprednisolone | 78 | 64 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 74 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 70 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 70 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 69 | 39 |
| Carvedilol | Carvedilol | 68 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 68 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 35 |
| Allopurinol | Allopurinol | 61 | 20 |
| Azithromycin | Azithromycin | 60 | 51 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 56 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 52 | 44 |
| Glipizide | Glipizide | 51 | 17 |
| Atenolol | Atenolol | 49 | 11 |
| Eliquis | Apixaban | 49 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 48 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 47 | 35 |
| Buspirone Hcl | Buspirone Hcl | 45 | 14 |
| Mirtazapine | Mirtazapine | 44 | 13 |
| Lorazepam | Lorazepam | 43 | 20 |
| Estradiol | Estradiol | 41 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | 12 |
| Spironolactone | Spironolactone | 38 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 32 |
| Fluconazole | Fluconazole | 31 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 31 | 14 |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | 12 |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 19 |
| Pregabalin | Pregabalin | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 17 |
| Venlafaxine Hcl | Venlafaxine Hcl | 25 | suppressed |
| Verapamil Er | Verapamil Hcl | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | 11 |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Prednisone | Prednisone | 15 | 12 |
| Torsemide | Torsemide | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Cefdinir | Cefdinir | 13 | 12 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Norvasc | Amlodipine Besylate | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Methylphenidate Er (La) | Methylphenidate Hcl | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $769.82 · 41 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, COMIRNATY, Dexcom G6 Transmitter, EVENITY, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, LOKELMA, MOUNJARO, Ozempic, PREVNAR 20, PROLIA, Rybelsus, SHINGRIX, SIMPONI ARIA, TREMFYA, TZIELD, The Cologuard Plus Collection Kit, Tymlos, VYNDAQEL, Wegovy, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error